Background Metformin is the most widely prescribed drug to lower glucose and has a
definitive effect on the cardiovascular system. The goal of this systematic review and meta …

Aging has been targeted by genetic and dietary manipulation and by drugs in order to
increase lifespan and health span in numerous models. Metformin, which has demonstrated …

Atrial fibrillation (AF) affects more than 33 million individuals worldwide and has a complex
heritability. We conducted the largest meta-analysis of genome-wide association studies …

The safety and efficacy of anti-diabetic drugs are critical for maximizing the beneficial
impacts of well-controlled blood glucose on the prognosis of individuals with COVID-19 and …

Metformin is currently the first-line drug treatment for type 2 diabetes. Besides its glucose-
lowering effect, there is interest in actions of the drug of potential relevance to cardiovascular …

Diabetes mellitus-related cardiomyopathy (DMCMP) was originally described as a dilated
phenotype with eccentric left ventricular (LV) remodelling and systolic LV dysfunction …

Heart failure (HF) is growing to a modern epidemic and despite advances in therapy, it still
carries an ominous prognosis and a significant socioeconomic burden. 1 Many novel agents …

Type 2 diabetes mellitus (T2DM) is a worldwide major health burden and heart failure (HF)
is the most common cardiovascular (CV) complication in affected patients. Therefore …

It has become widely accepted that inflammation is a driving force behind a variety of
chronic diseases, such as cardiovascular disease, diabetes, kidney disease, cancer …

Background Metformin, the eldest and most widely used glucose lowering drug, is likely to
be effective also on cardiac and vascular disease prevention. Nonetheless, uncertainty still …